CN115209900A - 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物 - Google Patents

用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物 Download PDF

Info

Publication number
CN115209900A
CN115209900A CN202180017888.8A CN202180017888A CN115209900A CN 115209900 A CN115209900 A CN 115209900A CN 202180017888 A CN202180017888 A CN 202180017888A CN 115209900 A CN115209900 A CN 115209900A
Authority
CN
China
Prior art keywords
oxo
oxy
fluorophenyl
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017888.8A
Other languages
English (en)
Chinese (zh)
Inventor
申在植
高永玉
李敏基
金用锡
崔淳珍
林娜廷
金民和
李准炯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weimaike Biology Co ltd
Original Assignee
Weimaike Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weimaike Biology Co ltd filed Critical Weimaike Biology Co ltd
Publication of CN115209900A publication Critical patent/CN115209900A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
CN202180017888.8A 2020-03-03 2021-03-03 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物 Pending CN115209900A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200026381 2020-03-03
KR10-2020-0026381 2020-03-03
PCT/KR2021/002622 WO2021177721A1 (ko) 2020-03-03 2021-03-03 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
CN115209900A true CN115209900A (zh) 2022-10-18

Family

ID=77612768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017888.8A Pending CN115209900A (zh) 2020-03-03 2021-03-03 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物

Country Status (6)

Country Link
US (1) US20230099204A1 (cg-RX-API-DMAC10.html)
EP (1) EP4115887A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023516381A (cg-RX-API-DMAC10.html)
KR (1) KR20210111711A (cg-RX-API-DMAC10.html)
CN (1) CN115209900A (cg-RX-API-DMAC10.html)
WO (1) WO2021177721A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206883A (zh) * 2019-08-02 2022-03-18 伟迈可生物有限公司 氧代吡啶稠环衍生物及包含该衍生物的药物组合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
KR20230144483A (ko) * 2022-04-06 2023-10-16 웰마커바이오 주식회사 Ron 돌연변이와 관련된 두경부암 예방 또는 치료용 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
CN104379563A (zh) * 2012-04-10 2015-02-25 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
WO2019182274A1 (en) * 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CN115003307A (zh) * 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101390076B1 (ko) 2006-11-08 2014-04-29 브리스톨-마이어스 스큅 컴퍼니 피리디논 화합물
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
WO2016018087A1 (ko) * 2014-07-29 2016-02-04 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
CN107406492B (zh) * 2014-09-03 2021-12-24 井标记生物 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途
EP4011885A4 (en) 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
JP2022554042A (ja) * 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206679A1 (en) * 2011-06-09 2014-07-24 Shanghai Huilun Life Science & Technology Co., Ltd Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
CN104379563A (zh) * 2012-04-10 2015-02-25 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
WO2019182274A1 (en) * 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CN115003307A (zh) * 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KYLE C. CUNEO等: "Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib", 《TRANSLATIONAL ONCOLOGY》, vol. 12, no. 2, pages 215 *
MICHELE L BABICKY等: "MST1R Kinase Accelerates Pancreatic Cancer Progression Via Effects on both Epithelial Cells and Macrophages", 《ONCOGENE》, vol. 38, no. 28, 9 April 2019 (2019-04-09), pages 5604 - 5605, XP036831792, DOI: 10.1038/s41388-019-0811-9 *
OGECHI N. IKEDIOBI等: "Mutation analysis of 24 known cancer genes in the NCI-60 cell line set", 《MOLECULAR CANCER THERAPEUTICS》, vol. 5, no. 11, 1 November 2006 (2006-11-01), pages 3 - 4, XP055267813, DOI: 10.1158/1535-7163.MCT-06-0433 *
XIANG-MING XU等: "RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells", 《ONCOGENE》, vol. 23, no. 52, 20 September 2004 (2004-09-20), pages 8468, XP037739467, DOI: 10.1038/sj.onc.1207907 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206883A (zh) * 2019-08-02 2022-03-18 伟迈可生物有限公司 氧代吡啶稠环衍生物及包含该衍生物的药物组合物

Also Published As

Publication number Publication date
WO2021177721A1 (ko) 2021-09-10
EP4115887A1 (en) 2023-01-11
JP2023516381A (ja) 2023-04-19
US20230099204A1 (en) 2023-03-30
EP4115887A4 (en) 2024-07-17
KR20210111711A (ko) 2021-09-13

Similar Documents

Publication Publication Date Title
KR20210111711A (ko) Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
US20230346790A1 (en) Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation
US11541027B2 (en) Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases
TWI680760B (zh) 治療黑色素瘤的藥物組合
US20080207572A1 (en) Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
TWI824010B (zh) 治療血癌之組合療法
WO2021018032A1 (en) Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
WO2017042634A2 (en) Use of dianhydrogalactitol or derivatives and analogs thereof for treatment of non-small-cell lung carcinoma, glioblastoma, and ovarian carcinoma by induction of dna damage and stalling of cell cycle
CN101820915A (zh) 用于治疗癌症的方法和组合物
SG194047A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
CN116685324A (zh) 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法
HK40102341A (en) A pharmaceutical combination for the treatment of melanoma
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
HK1244482A1 (zh) 用於治疗神经母细胞瘤的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221018